Face to Face: deciphering facial involvement in inclusion body myositis
- 23 September 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (1) , 410-418
Abstract
Objective The objective of this study is to evaluate the frequency and characteristics of facial involvement in inclusion body myositis (IBM) patients and to compare it to the one previously described in facioscapulohumeral dystrophy (FSHD) patients. Methods Thirty-two IBM patients were included and compared to 29 controls and 39 FSHD patients. All participants were recorded in a video as they performed a series of seven facial tasks. Five raters independently assessed facial weakness using both a qualitative evaluation and a semi-quantitative facial weakness score (FWS). Results IBM patients had higher FWS than controls (7.89 ± 7.56 vs 1.06 ± 0.88, p < 0.001). Twenty IBM patients (63%) had a facial weakness with a FWS above the maximum value for controls. All facial tasks were significantly more impaired in IBM patients compared to controls (p < 0.001), task 2 evaluating orbiculari oculi muscle weakness being the most affected. IBM patients with facial weakness reported more swallowing troubles than IBM patients without facial weakness (p = 0.03). FSHD patients displayed higher FWS than IBM patients (12.16 ± 8.37 vs 7.89 ± 7.56, p = 0.01) with more pronounced facial asymmetry (p = 0.01). FWS inter-rater ICC was 0.775. Conclusion This study enabled us to estimate the frequency of facial impairment in IBM in more than half of patients, to detail its characteristics and to compare them with those of FSHD patients. The standardized, semi-quantitative FWS is an interesting diagnostic help in IBM as it appeared more sensitive than qualitative evaluation to detect mild facial weakness.Keywords
This publication has 35 references indexed in Scilit:
- Atypical onset in a series of 122 cases with FacioScapuloHumeral Muscular DystrophyClinical Neurology and Neurosurgery, 2012
- Focal and other unusual presentations of facioscapulohumeral muscular dystrophyMuscle & Nerve, 2012
- A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilitiesBrain, 2011
- Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north‐east Italian population sampleClinical Genetics, 2009
- Inclusion body myositis functional rating scale: A reliable and valid measure of disease severityMuscle & Nerve, 2008
- Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian casesJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Facioscapulohumeral muscular dystrophyMuscle & Nerve, 2006
- Inclusion Body Myositis in ConnecticutMedicine, 2001
- Inclusion body myositis: Clinical and pathological boundariesAnnals of Neurology, 1996
- Spectrum of Inclusion Body MyositisArchives of Neurology, 1987